Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Open access

Abstract

Background Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups. We aimed to examine the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab combination as an immunotherapeutic boost after no response to nivolumab monotherapy in patients with intermediate-risk and poor-risk clear-cell metastatic renal cell carcinoma.Methods TITAN-RCC is a multicentre, single-arm, phase 2 trial, done at 28 hospitals and cancer centres across Europe (Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, and the UK). Adults (aged ≥18 years) with histologically confirmed intermediate-risk or poor-risk clear-cell metastatic renal cell carcinoma who were formerly untreated (first-line population) or pretreated with one previous systemic therapy (anti-angiogenic or temsirolimus; second-line population) were eligible. Patients had to have a Karnofsky Performance Status score of at least 70 and measurable disease per Response Evaluation Criteria in Solid Tumours (version 1.1). Patients started with intravenous nivolumab 240 mg once every 2 weeks. On early progressive disease (week 8) or non-response at week 16, patients received two or four doses of intravenous nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) boosts (once every 3 weeks), whereas responders continued with intravenous nivolumab (240 mg, once every 2 weeks), but could receive two to four boost doses of nivolumab plus ipilimumab for subsequent progressive disease. The primary endpoint was confirmed investigator-assessed objective response rate in the full analysis set, which included all patients who received at least one dose of study medication; safety was also assessed in this population. An objective response rate of more than 25% was required to reject the null hypothesis and show improvement, on the basis of results from the pivotal phase 3 CheckMate-025 trial. This study is registered with ClinicalTrials.gov, NCT02917772, and is complete.Findings Between Oct 28, 2016, and Nov 30, 2018, 207 patients were enrolled and all received nivolumab induction (109 patients in the first-line group; 98 patients in the second-line group). 60 (29%) of 207 patients were female and 147 (71%) were male. 147 (71%) of 207 patients had intermediate-risk metastatic renal cell carcinoma and 51 (25%) had poor-risk disease. After median follow-up of 27·6 months (IQR 10·5-34·8), 39 (36%, 90% CI 28-44; p=0·0080) of 109 patients in the first-line group and 31 (32%, 24-40; p=0·083) of 98 patients in the second-line group had a confirmed objective response for nivolumab with and without nivolumab plus ipilimumab. Confirmed response to nivolumab at week 8 or 16 was observed in 31 (28%) of 109 patients in the first-line group and 18 (18%) of 98 patients in the second-line group. The most frequent grade 3-4 treatment-related adverse events (reported in ≥5% of patients) were increased lipase (15 [7%] of 207 patients), colitis (13 [6%]), and diarrhoea (13 [6%]). Three deaths were reported that were deemed to be treatment-related: one due to possible ischaemic stroke, one due to respiratory failure, and one due to pneumonia.Interpretation In treatment-naive patients, nivolumab induction with or without nivolumab plus ipilimumab boosts significantly improved the objective response rate compared with that reported for nivolumab monotherapy in the CheckMate-025 trial. However, overall efficacy seemed inferior when compared with approved upfront nivolumab plus ipilimumab. For second-line treatment, nivolumab plus ipilimumab could be a rescue strategy on progression with approved nivolumab monotherapy.Funding Bristol Myers Squibb.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00449-7

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Choueiri, 2022, Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313), Ann Oncol, 33, S808

Cited by

See all 37

Metadata

Authors
Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., Foller, S., Baretton, G., Duran, I., de Velasco, G., Priou, F., Maroto, P., Albiges, L., Barone, C., Castellano, D., Chevreau, C., Gajate Borau, P., Gopalakrishnan, S., Grande, E., Hamid, A., Heinzelbecker, J., Janssen, M., Kopecký, J., Kubala, E., Loidl, W., Lorch, A., Melichar, B., Lainez Milagro, N., Niegisch, G., Ohlmann, C., Sacré, A., Sarwar, N., Schinzari, G., Schrijvers, D., Tartas, S., Wirth, M., Wolter, P., & Zemanova, M.
Affiliations
  • Jena University Hospital (DE)
  • Hospital Universitario Central de Asturias (ES)
  • Institut de Cancérologie Strasbourg (FR)
  • Medical University of Vienna (AT)
  • Charité – Universitätsmedizin Berlin (DE)
  • Hospital Universitario Virgen del Rocío (ES)
  • Royal Preston Hospital (GB)
  • German Cancer Research Center (DE)
  • Technische Universität Dresden (DE)
  • Centre Hospitalier Départemental Vendée (FR)
  • Hospital de Sant Pau (ES)
  • Université Paris-Saclay (FR)
Corresponding author
Grimm, Marc-Oliver
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-11
Volume
24
Issue
11
Pages
1252-1265
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4387610648
Cited by
37
References
17
Citations by year
2026: 9 · 2025: 14 · 2024: 13 · 2023: 1
FWCI
6.80
Type
journal article
Language
en
Open access
Locations
  • The Lancet Oncology (acceptedVersion)
  • PubMed (publishedVersion)
Funders
  • BMS
  • AIO-Studien
  • Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
metastatic renal cell carcinoma, clear cell renal cell carcinoma, nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, objective response rate, second-line therapy, treatment safety, anti-angiogenic therapy, temsirolimus
MeSH terms
Ipilimumab, Nivolumab, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Brain Ischemia, Female, Humans, Immunotherapy, Kidney Neoplasms, Male, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00449-7
The paper
Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., Foller, S., Baretton, G., Duran, I., de Velasco, G., Priou, F., Maroto, P., Albiges, L., Barone, C., Castellano, D., . . . Zemanova, M. (2023). Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00449-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.